ACT 451840

Drug Profile

ACT 451840

Alternative Names: ACT-451840; Malaria therapy - Actelion

Latest Information Update: 02 May 2016

Price : $50

At a glance

  • Originator Actelion Pharmaceuticals; Swiss Tropical and Public Health Institute
  • Developer Actelion Pharmaceuticals
  • Class Antimalarials; Piperazines; Small molecules
  • Mechanism of Action Aspartic endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Malaria

Most Recent Events

  • 02 May 2016 No development reported - Phase-I for Malaria (In volunteers) in Australia (PO)
  • 02 May 2016 No development reported - Phase-I for Malaria (In volunteers) in France (PO)
  • 28 Jul 2014 ACT 451840 is available for licensing as of 28 July 2014 (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top